Aly 2007.

Methods	Design: randomised, placebo‐controlled, parallel‐group trial
Participants	Number assigned: 60 children (macrolide n = 30, placebo n = 30) Age in days (median (range)): macrolide: 2.0 (2.0 to 24.0), placebo: 2.0 (2.0 to 10.0) Setting: secondary care
Interventions	Indication: feeding intolerance in preterm infants Type of macrolide: erythromycin ethylsuccinate Route: per oral Dose per day: 3 mg/kg Duration of treatment: the study medicine was to stop once the primary endpoint was achieved Total treatment dose: N/A
Outcomes	Adverse events stated as an outcome in trial registration/protocol/paper: no Adverse events ascertainment: unclear Adverse events: data reported Antimicrobial resistance: not reported Death: data reported
Funding sources	None reported.
Notes	Concomitant medication: yes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Block randomisation
Allocation concealment (selection bias)	Low risk	Allocation concealed by cards provided in consecutively numbered, opaque, sealed envelopes.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Both active drug and placebo were mixed thoroughly into the milk feeds by designated staff not involved in the clinical management of the infants.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Parents and staff blinded.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Low dropout, similar across groups
Selective reporting (reporting bias)	Unclear risk	Adverse events not stated as an outcome and unclear ascertainment. Adverse events/complications reported.
Other bias	Low risk	None were identified.